{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:51:32Z","timestamp":1788922292423,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd009377.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,7,31]],"date-time":"2017-07-31T00:00:00Z","timestamp":1501459200000}}],"reference-count":323,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,7,31]],"date-time":"2017-07-31T00:00:00Z","timestamp":1501459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,7,31]],"date-time":"2017-07-31T00:00:00Z","timestamp":1501459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009377.pub3","type":"journal-article","created":{"date-parts":[[2017,7,31]],"date-time":"2017-07-31T07:53:41Z","timestamp":1501487621000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation)"],"prefix":"10.1002","volume":"2017","author":[{"given":"Edoardo G","family":"Ostinelli","sequence":"first","affiliation":[{"name":"Universit\u00e0 degli Studi di Milano; Department of Health Sciences; Via Antonio di Rudin\u00ec 8 Milan Italy 20142"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie J","family":"Brooke-Powney","sequence":"additional","affiliation":[{"name":"The University of Manchester; Department of Clinical Psychology; 2nd Floor, Zochonis Building Brunswick Street Manchester UK M13 9PL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Li","sequence":"additional","affiliation":[{"name":"Systematic Review Solutions Ltd; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive E","family":"Adams","sequence":"additional","affiliation":[{"name":"The University of Nottingham; Cochrane Schizophrenia Group; Institute of Mental Health Innovation Park, Triumph Road, Nottingham UK NG7 2TU"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,7,31]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD009377.pub3-BIB0001|cit1","first-page":"127","article-title":"Comparison of IM haloperidol and IM chlorpromazine in the treatment of acutely psychotic patients","volume":"18","author":"Bailine","year":"1987","journal-title":"Psychiatric Hospital"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"Baldacara L Sanches M Cordeiro DC Jackoswski AP Rapid tranquilization for agitated patients in emergency psychiatric rooms: A randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone Revista Brasileira de Psiquiatria 2011 30 9","DOI":"10.1590\/S1516-44462011000100008"},{"issue":"4","key":"10.1002\/14651858.CD009377.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0735-6757(97)90119-4","article-title":"Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study","volume":"15","author":"Battaglia","year":"1997","journal-title":"American Journal of Emergency Medicine"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD009377.pub3-BIB0004|cit4","first-page":"183","article-title":"Calming versus sedative effects of IM olanzapine in agitated patients","volume":"53","author":"Battaglia","year":"2002","journal-title":"Schizophrenia Research"},{"issue":"10","key":"10.1002\/14651858.CD009377.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.clinthera.2005.10.001","article-title":"A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia","volume":"27","author":"Battaglia","year":"2005","journal-title":"Clinical Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD009377.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0735-6757(02)42249-8","article-title":"Calming versus sedative effects of intramuscular olanzapine in agitated patients","volume":"21","author":"Battaglia","year":"2003","journal-title":"American Journal of Emergency Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009377.pub3-BIB0007|cit7","first-page":"104s","article-title":"Calming versus sedative effects of IM olanzapine in agitated patients","volume":"17","author":"David","year":"2002","journal-title":"Proceedings of the 11th Congress of the Association of European Psychiatrists; 2002 May 4-8; Stockholm, Sweden"},{"issue":"3","key":"10.1002\/14651858.CD009377.pub3-BIB0008|cit8","first-page":"276","article-title":"Analysis of the QTC interval in acutely agitated patients with schizophrenia, bipolar mania, or dementia treated with intramuscular (IM) olanzapine vs. IM placebo or IM haloperidol","volume":"11","author":"David","year":"2001","journal-title":"European Neuropsychopharmacology"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD009377.pub3-BIB0009|cit9","first-page":"164","article-title":"QTC intervals during treatment with IM olanzapine in acutely agitated patients","volume":"53","author":"David","year":"2002","journal-title":"Schizophrenia Research"},{"issue":"1-2","key":"10.1002\/14651858.CD009377.pub3-BIB0010|cit10","first-page":"224","article-title":"Intramuscular olanzapine versus intramuscular haloperidol and intramuscular placebo: an international double-blind study in acutely agitated patients with schizophrenia","volume":"49","author":"David","year":"2001","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0011|cit11","unstructured":"Houston JP Kaiser CJ Ahl J Oral olanzapine transition dose following intramuscular olanzapine treatment International Congress on Schizophrenia Research; 2005 Apr 2-5, Savanagh, Georgia USA 2005"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0012|cit12","doi-asserted-by":"crossref","unstructured":"King KG Wright P Meehan K Birkett M David SR Taylor CC Transition from intramuscular to oral olanzapine Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan 2002","DOI":"10.1016\/S0924-9338(02)80468-0"},{"issue":"1-2","key":"10.1002\/14651858.CD009377.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0165-1781(03)00107-0","article-title":"Effects of intramuscular olanzapine vs haloperidol and placebo on QTc intervals in acutely agitated patients","volume":"119","author":"Lindborg","year":"2003","journal-title":"Psychiatry Research"},{"issue":"2","key":"10.1002\/14651858.CD009377.pub3-BIB0014|cit14","first-page":"197","article-title":"Short-acting intramuscular olanzapine in acutely agitated schizophrenic patients: A randomized double blind trial vs. placebo and haloperidol","volume":"42","author":"Meehan","year":"2001","journal-title":"Psychosomatics"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0015|cit15","unstructured":"Meehan K Wright P David SR Alaka K Taylor CC Breier A Agitation as a treatable symptom common to schizophrenia, acute mania and dementia Proceedings of the 57th Annual Meeting of the Society of Biological Psychiatry; 2002 May 16-18; Philadelphia, Pennsylvania, USA 2002"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD009377.pub3-BIB0016|cit16","first-page":"63","article-title":"Agitation as a treatable symptom common to schizophrenia, acute mania, and dementia","volume":"53","author":"Meehan","year":"2002","journal-title":"Schizophrenia Research"},{"issue":"7","key":"10.1002\/14651858.CD009377.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1176\/appi.ajp.158.7.1149","article-title":"Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia","volume":"158","author":"Wright","year":"2001","journal-title":"American Journal of Psychiatry"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009377.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1016\/S0924-977X(00)80344-2","article-title":"A double-blind study of intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients","volume":"10","author":"Wright","year":"2000","journal-title":"European Neuropsychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009377.pub3-BIB0019|cit19","first-page":"S139","article-title":"A double-blind study of intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients","volume":"3","author":"Wright","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD009377.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1177\/070674370304801102","article-title":"Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment","volume":"48","author":"Wright","year":"2003","journal-title":"Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]"},{"issue":"5","key":"10.1002\/14651858.CD009377.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/S0149-2918(03)80129-7","article-title":"A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy","volume":"25","author":"Wright","year":"2003","journal-title":"Clinical Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD009377.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/archpsyc.59.5.441","article-title":"A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia","volume":"59","author":"Breier","year":"2002","journal-title":"Archives of General Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD009377.pub3-BIB0023|cit23","first-page":"121S","article-title":"A double-blind dose response study comparing intramuscular (IM) olanzapine, haloperidol, and placebo in acutely agitated schizophrenic patients","volume":"49","author":"Breier","year":"2001","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0024|cit24","doi-asserted-by":"crossref","unstructured":"Breier A Wright P Birkett M Meehan K David S Brook S A double-blind dose response study comparing intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico 2000","DOI":"10.1016\/S0924-977X(00)80344-2"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0025|cit25","unstructured":"Breier AF Wright P Birkett M Meehan K David SR Brook S Intramuscular olanzapine: dose-related improvement in acutely agitated patients with schizophrenia Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA Marathon Multimedia 2001"},{"issue":"1","key":"10.1002\/14651858.CD009377.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/ebmh.6.1.27","article-title":"10 mg intramuscular olanzapine reduces acute agitation in schizophrenia more effectively than lower doses [Commentary]","volume":"6","author":"Smith","year":"2003","journal-title":"Evidence-Based Mental Health"},{"issue":"1-2","key":"10.1002\/14651858.CD009377.pub3-BIB0027|cit27","first-page":"250","article-title":"A double-blind dose response study comparing intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients","volume":"49","author":"Wright","year":"2001","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1002\/14651858.CD009377.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00213-006-0541-x","article-title":"Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol","volume":"188","author":"Andrezina","year":"2006","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD009377.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1185\/030079906X148445","article-title":"Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study","volume":"22","author":"Andrezina","year":"2006","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0030|cit30","unstructured":"Bristol-Myers S A randomized, double-blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder http:\/\/www.clinicalstudyresults.org\/ 2004"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0031|cit31","unstructured":"Citrome LL Vester-Blokland E Archibald D McQuade R Kostic D Pikalov A Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada 2006"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0032|cit32","unstructured":"Currier GW Crandall D Archibald D Nyilas M Kostic D Pikalov A Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada 2006"},{"issue":"3","key":"10.1002\/14651858.CD009377.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/01.pra.0000271658.86845.81","article-title":"Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations","volume":"13","author":"Daniel","year":"2007","journal-title":"Journal of Psychiatric Practice"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0034|cit34","unstructured":"Daniel DG Stock EG Wilber CH Marcus RN Carson WH Jr Manos G Intramuscular aripiprazole in acutely agitated psychotic patients Proceedings of the 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, USA 2004"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009377.pub3-BIB0035|cit35","first-page":"S509","article-title":"Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients","volume":"15","author":"Dillenschneider","year":"2005","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0036|cit36","unstructured":"Dillenschneider A Oren D Marcus R Kostic D McQuade R Iwamoto T Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study Proceedings of the 18th European College of Neuropsychopharmacology Congress; 2005 Oct 22-26; Amsterdam, Netherlands 2005"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0037|cit37","unstructured":"McQuade R Auby P Oren D Marcus R Kostic D Iwamoto T Intramuscular aripiprazole in acute schizophrenia: a double-blind, placebo-controlled comparison with IM haloperidol Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland 2006"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0038|cit38","first-page":"499","article-title":"Efficacy and safety of intramuscular aripiprazole, haloperidol or PLACEBO in acutely agitated patients with schizophrenia or schizoaffective disorder","volume":"31","author":"Oren","year":"2005","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0039|cit39","unstructured":"Oren D Marcus R Kostic D McQuade R Iwamoto T Archibald D Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta, Georgia, USA 2005"},{"issue":"2","key":"10.1002\/14651858.CD009377.pub3-BIB0040|cit40","first-page":"451","article-title":"Non-inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia\/schizoaffective disorder","volume":"33","author":"Oren","year":"2007","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0041|cit41","unstructured":"Yocca F Marcus R Oren D Manos G Carson W Iwamoto T Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26, Atlanta, Georgia, USA 2005"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0042|cit42","unstructured":"Bristol-Myers S Randomized, double-blind, dose-ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder http:\/\/www.clinicalstudyresults.org\/ 2005"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0043|cit43","unstructured":"Currier GW Crandall D Archibald D Nyilas M Kostic D Pikalov A Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada 2006"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009377.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.1016\/S0924-977X(04)80286-4","article-title":"Intramuscular aripiprazole treatment for acute agitation in patients with psychosis","volume":"14","author":"Gismondi","year":"2004","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0045|cit45","doi-asserted-by":"crossref","unstructured":"Kungel M Czaniera R Ebrecht M Werner C Oren D McQuade R Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double-blind controlled study to find the dosage Proceedings of the 25th Symposium of the Arbeitsgemeinschaft Neuropsychopharmakologie und Pharmakopsychiatrie; 2007 Oct 3-6; Munich, Germany 2007","DOI":"10.1055\/s-2007-991772"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0046|cit46","unstructured":"Kungel M Daniel D Stock E Wilber R Marcus R Carson W Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis Proceedings of the Thematic Conference of the World Psychiatric Association on \"Treatments in Psychiatry: An Update\"; 2004 Nov 10-13; Florence, Italy 2004"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/j.eurpsy.2007.01.397","article-title":"Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub-analysis of a double-blind, controlled, dose-ranging study","volume":"22","author":"Oren","year":"2007","journal-title":"European Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD009377.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4088\/JCP.v68n0115","article-title":"Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial","volume":"68","author":"Tran-Johnson","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0049|cit49","unstructured":"Brook S Krams M Gunn K Intramuscular (IM) ziprasidone vs. IM haloperidol in patients with acute, non-organic psychosis Proceedings of the 9th Congress of the Association of European Psychiatrists; 1998 Sep 20-24; Copenhagen, Denmark 1998"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0051|cit50","unstructured":"Brook S Krams M Gunn KP Intramuscular ziprasidone versus intramuscular haloperidol Proceedings of the 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 1998 Jul 12-16; Glasgow, UK 1998"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0050|cit51","doi-asserted-by":"crossref","unstructured":"Brook S Krams M Gunn KP and the Ziprasidone IM Study Group The efficacy and tolerability of intramuscular (IM) ziprasidone versus IM haloperidol in patients with acute non-organic psychosis Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 - Jun 4; Toronto, Ontario, Canada 1998","DOI":"10.1016\/S0924-9338(99)80609-9"},{"issue":"12","key":"10.1002\/14651858.CD009377.pub3-BIB0052|cit52","first-page":"933","article-title":"Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis","volume":"61","author":"Brook","year":"2000","journal-title":"Journal of Clinical Psychological Medicine [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009377.pub3-BIB0053|cit53","first-page":"S239","article-title":"An overview of the efficacy and safety of rapid acting intramuscular ziprasidone","volume":"10","author":"Daniel","year":"2000","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0054|cit54","unstructured":"Zimbroff DL Daniel DG Brook S Reeves KR An overview of the efficacy and safety of rapid-acting intramuscular ziprasidone Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois, USA 2000"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0055|cit55","doi-asserted-by":"crossref","unstructured":"Calver L Drinkwater V Gupta R Page CB Isbister GK Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: Randomized controlled trial British Journal of Psychiatry 2015 223 8","DOI":"10.1192\/bjp.bp.114.150227"},{"issue":"3","key":"10.1002\/14651858.CD009377.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"386","DOI":"10.4088\/JCP.v65n0315","article-title":"Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam","volume":"65","author":"Currier","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD009377.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1176\/ajp.156.1.142","article-title":"Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior","volume":"156","author":"Dorevitch","year":"1999","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0058|cit58","doi-asserted-by":"crossref","unstructured":"Chan HY Ree SC Su LW Chen JJ Chou SY Chen CK A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior Journal of Clinical Psychopharmacology 2014 355 8","DOI":"10.1097\/JCP.0000000000000120"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0059|cit59","unstructured":"Eli Lilly Comparison of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia Eli Lilly and Company Clinical Trial Registry 2004"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0060|cit60","unstructured":"NCT00485901 A double-blind randomized comparison of the efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in acutely agitated patients with schizophrenia http:\/\/www.clinicaltrials.gov 2007"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0061|cit61","doi-asserted-by":"crossref","unstructured":"Fang M Chen H Li LH Wu R Li Y Liu L Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia International Clinical Psychopharmacology 2012 107 13","DOI":"10.1097\/YIC.0b013e32834fc431"},{"issue":"8","key":"10.1002\/14651858.CD009377.pub3-BIB0062|cit62","first-page":"515","article-title":"A double-blind comparison of haloperidol with perphenazine in acute psychiatric episodes","volume":"11","author":"Fitzgerald","year":"1969","journal-title":"Current Therapeutic Research"},{"issue":"3","key":"10.1002\/14651858.CD009377.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00004850-199705000-00009","article-title":"Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting","volume":"12","author":"Foster","year":"1997","journal-title":"International Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD009377.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1600-0447.1977.tb00226.x","article-title":"Loxapine versus haloperidol parenterally in acute psychosis with agitation. A double-blind study","volume":"56","author":"Fruensgaard","year":"1977","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"12","key":"10.1002\/14651858.CD009377.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1176\/ajp.146.12.1598","article-title":"Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation","volume":"146","author":"Garza-Trevino","year":"1989","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD009377.pub3-BIB0066|cit66","first-page":"183","article-title":"Study of quetiapine combined with magnesium valproate release tablets in treatment of schizophrenia with symptoms of elation and agitation","volume":"17","author":"Guo","year":"2007","journal-title":"Linchuang Jingshen Yixue Zazhi [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"6","key":"10.1002\/14651858.CD009377.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.eurpsy.2004.07.001","article-title":"Combined therapy with low-potency neuroleptic levomepromazine as an adjunct to haloperidol for agitated patients with acute exacerbation of schizophrenia","volume":"19","author":"Higashima","year":"2004","journal-title":"European Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD009377.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/ebmh.11.3.86","article-title":"Intramuscular haloperidol plus promethazine is more effective and safer than haloperidol alone for rapid tranquillisation of agitated mentally ill patients","volume":"11","author":"Barbui","year":"2008","journal-title":"Evidence-Based Mental Health"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0071|cit69","unstructured":"Huf G Haloperidol plus promethazine versus haloperidol for psychosis induced aggression Data on file 2004"},{"issue":"7625","key":"10.1002\/14651858.CD009377.pub3-BIB0069|cit70","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/bmj.39339.448819.AE","article-title":"Rapid tranquillisation in psychiatric emergency settings in Brazil: pragmatic randomised controlled trial of intramuscular haloperidol versus intramuscular haloperidol plus promethazine","volume":"335","author":"Huf","year":"2007","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0070|cit71","unstructured":"Huf G Coutinho ESF Adams CE The pharmacological management of agitated patients in emergency psychiatric hospitals in Rio de Janeiro, Brazil: the results of two pragmatic randomized clinical trials Proceedings of the 5th European Congress on Violence in Clinical Psychiatry; 2007 Oct 25-27; Amsterdam, The Netherlands 2007"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0072|cit72","unstructured":"ISRCTN83261243 TREC2 - Rapid tranquillisation for agitated patients in emergency psychiatric rooms in Rio de Janeiro. A randomised trial of intramuscular haloperidol versus intramuscular haloperidol + promethazine http:\/\/www.controlled-trials.com 2005"},{"issue":"3","key":"10.1002\/14651858.CD009377.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.genhosppsych.2007.12.005","article-title":"Factors associated with the use of physical restraints for agitated patients in psychiatric emergency rooms","volume":"30","author":"Migon","year":"2008","journal-title":"General Hospital Psychiatry"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0278-5846(84)90138-6","article-title":"Rapid tranquilization: A comparative study of thiothixene and haloperidol","volume":"8","author":"Kewala","year":"1984","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009377.pub3-BIB0075|cit75","first-page":"S128","article-title":"Efficacy of olanzapine and adjunctive lorazepam to control agitation in schizophrenia","volume":"5","author":"Kinon","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD009377.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajem.2004.02.021","article-title":"Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia","volume":"22","author":"Kinon","year":"2004","journal-title":"American Journal of Emergency Medicine"},{"issue":"3","key":"10.1002\/14651858.CD009377.pub3-BIB0077|cit77","first-page":"278","article-title":"The efficacy of olanzapine plus adjunctive lorazepam to control acute agitation in schizophrenia","volume":"11","author":"Kinon","year":"2001","journal-title":"European Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD009377.pub3-BIB0078|cit78","first-page":"216","article-title":"A comparative study of intramuscular ziprasidone and haloperidol in treating acute agitation in schizophrenia","volume":"39","author":"Li","year":"2006","journal-title":"Chinese Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0079|cit79","unstructured":"Liang Y Su Y Huang J Tang M Li K Yang F Effect of quetiapine and haloperidol on QTc interval in treating schizophrenic patients with excitement and agitation Chinese New Drugs Journal [Zhongguo Xin Yao Za Zhi; \u4e2d\u56fd\u65b0\u836f\u6742\u5fd7] 2013 1886 9+1894"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0080|cit80","unstructured":"Liang Y Su Y Huang J Tang M Li K Yang P A randomized controlled study of effect and safety of quetiapine and haloperidol in treatment of schizophrenic patients with excitement and agitation Chinese Mental Health Journal [Zhongguo Xin Li Wei Sheng Za Zhi; \u4e2d\u56fd\u5fc3\u7406\u536b\u751f\u6742\u5fd7] 2013 262 7"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD009377.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"S467","DOI":"10.1016\/S0924-977X(07)70712-5","article-title":"Risperidone orodispersible tablet and intramuscular haloperidol in treatment of acute psychotic agitation","volume":"17","author":"Kim","year":"2007","journal-title":"European Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD009377.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000315437","article-title":"Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: A randomized open, prospective study","volume":"62","author":"Lim","year":"2010","journal-title":"Neuropsychobiology"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0083|cit83","unstructured":"\u5218\u951f \u5218\u4e91 \u5b81\u5357\u4e49 \u5b59\u5efa\u4e2d \u5b59\u4e9a\u519b \u5b59\u540c\u52cb Consolidation of short-term risperidone intramuscular haloperidol in the treatment of acute agitation in schizophrenia randomized controlled study of the efficacy of behavior [Google Translate] \u4e2d\u56fd\u533b\u836f\u5bfc\u62a5 2012 104 6"},{"issue":"1","key":"10.1002\/14651858.CD009377.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0033-3182(73)71377-3","article-title":"Rapid tranquilization of acutely psychotic patients with intramuscular haloperidol and chlorpromazine","volume":"14","author":"Man-Pang","year":"1973","journal-title":"Psychosomatics"},{"issue":"7","key":"10.1002\/14651858.CD009377.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1553-2712.2004.tb00738.x","article-title":"A prospective, double-blind, randomized trial of midazolam versus haloperidol versus lorazepam in the chemical restraint of violent and severely agitated patients","volume":"11","author":"Nobay","year":"2004","journal-title":"Academic Emergency Medicine"},{"issue":"1","key":"10.1002\/14651858.CD009377.pub3-BIB0086|cit86","first-page":"80","article-title":"A double-blind comparison between loxapine and haloperidol by parenteral route in acute schizophrenia","volume":"21","author":"Paprocki","year":"1977","journal-title":"Current Therapeutic Research"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0087|cit87","first-page":"112","article-title":"Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia","volume":"35","author":"Reshke","year":"1974","journal-title":"Diseases of the Nervous System"},{"issue":"7","key":"10.1002\/14651858.CD009377.pub3-BIB0088|cit88","first-page":"298","article-title":"Droperidol vs. haloperidol in the initial management of acutely agitated patients","volume":"45","author":"Resnick","year":"1984","journal-title":"Journal of Clinical Psychological Medicine [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"1","key":"10.1002\/14651858.CD009377.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1176\/ajp.129.1.78","article-title":"Comparison of injectable haloperidol and chlorpromazine","volume":"129","author":"Ritter","year":"1972","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD009377.pub3-BIB0090|cit90","first-page":"177","article-title":"Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior","volume":"52","author":"Salzman","year":"1991","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0091|cit91","unstructured":"Shi Y Dai T Yi P olanzapine combined magnesium valproate sustained-release tablets in the treatment of schizophrenia, acute agitation excited [Google Translate] Modern Practical Medicine 2010 398 9"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0092|cit92","unstructured":"NCT00723606 A randomized, open-label, multi-center study to evaluate the efficacy and safety of intramuscular ziprasidone in patients with agitation http:\/\/www.clinicaltrials.gov 2008"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0093|cit93","unstructured":"Pfizer A randomized, open label, rater blind, flexible dose multi-center study comparing the efficacy and safety of intramuscular ziprasidone with haloperidol for three days in patients with agitation of schizophrenia http:\/\/www.clinicalstudyresults.org\/documents\/company-study_10505_0.pdf"},{"issue":"2-3","key":"10.1002\/14651858.CD009377.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.schres.2010.02.408","article-title":"Intramuscular ziprasidone has improved tolerability over haloperidol and comparable efficacy for control of agitation in schizophrenia in Chinese patients","volume":"117","author":"Shu","year":"2010","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0095|cit95","doi-asserted-by":"crossref","unstructured":"Zhang H Wang G Zhao J Xie S Xu X Shi J Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia Journal of Clinical Psychopharmacology 2013 178 85","DOI":"10.1097\/JCP.0b013e3182839612"},{"issue":"12","key":"10.1002\/14651858.CD009377.pub3-BIB0096|cit96","first-page":"967","article-title":"Relative efficacy of parenteral haloperidol and thiothixene for the emergency treatment of acutely excited and agitated patients","volume":"38","author":"Stotsky","year":"1977","journal-title":"Diseases of the Nervous System"},{"issue":"12","key":"10.1002\/14651858.CD009377.pub3-BIB0097|cit97","first-page":"1301","article-title":"Comparative study of the effectiveness of zuclopenthixol acetate and haloperidol in acutely disturbed psychotic patients","volume":"85","author":"Taymeeyapradit","year":"2002","journal-title":"Journal of the Medical Association of Thailand"},{"issue":"3","key":"10.1002\/14651858.CD009377.pub3-BIB0098|cit98","first-page":"126","article-title":"A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients","volume":"47","author":"Tuason","year":"1986","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0099|cit99","doi-asserted-by":"crossref","unstructured":"Walther S Moggi F Horn H Moskvitin K Abderhalden C Maier N Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine Journal of Clinical Psychopharmacology 2014 124 8","DOI":"10.1097\/JCP.0000000000000050"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0100|cit100","doi-asserted-by":"crossref","unstructured":"Walther S Moggi F Horn H Moskvitin K Maier N Abderhalden C Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: A naturalistic, rater-blinded, randomized controlled study with oral haloperidol, risperidone, and olanzapine PharmacoPsychiatry 2013 A77","DOI":"10.1055\/s-0033-1353338"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0101|cit101","unstructured":"\u5c39\u6790\u51e1 \u738b\u521a \u9f50\u62c9\u897f\u916e\u6ce8\u5c04\u6db2\u6cbb\u7597\u7cbe\u795e\u5206\u88c2\u75c7\u6fc0\u8d8a\u75c7\u72b6\u7684\u7814\u7a76 \u4e2d\u56fd\u5f53\u4ee3\u533b\u836f 2012 9 11"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0102|cit102","unstructured":"\u5468\u5347\u5b9d \u5b59\u6653\u4e39 \u5e9e\u7426 \u674e\u5fd7\u6885 \u8d75\u7ee7\u8212 \u5f20\u5cf0 \u9f50\u62c9\u897f\u916e\u8054\u5408\u6c2f\u785d\u897f\u6cee\u6cbb\u7597\u7cbe\u795e\u5206\u88c2\u75c7\u6025\u6027\u671f\u5174\u594b\u6fc0\u8d8a\u75c7\u72b6\u5bf9\u7167\u7814\u7a76 \u4e34\u5e8a\u5fc3\u8eab\u75be\u75c5\u6742\u5fd7 2014 17 20"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0103|cit103","doi-asserted-by":"crossref","unstructured":"Addington DE Arvanitis LA 'Seroquel' (quetiapine): an atypical antipsychotic - results from a multiple fixed dose, placebo-controlled study Proceedings of the 4th International Conference on Schizophrenia - 1996: Breaking down the Barriers; 1996 Oct 6-9; Vancouver, Canada 1996","DOI":"10.1016\/0924-977X(96)87987-9"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0104|cit104","unstructured":"Arvanitis LA Sweitzer DE Goldstein JM Yeung PP Serequel reduces aggression in patients with acute exacerbation of schizophrenia Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31 - Nov 4; Paris, France 1998"},{"issue":"2-3","key":"10.1002\/14651858.CD009377.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/0920-9964(96)85441-7","article-title":"A comparison of five fixed doses 'seroquel' (ICI 204,636) with haloperidol and placebo in patients with schizophrenia","volume":"18","author":"Borison","year":"1996","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0109|cit106","unstructured":"Cantillon M Quetiapine fumarate reduces aggression Proceedings of the 11th Annual Meeting of the American Association for Geriatric Psychiatry; 1998 Mar 8-11; San Diego, California, USA 1998"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0106|cit107","unstructured":"Cantillon M Arvanitis LA Miller BG Kowalcyk 'Seroquel' (quetiapine fumarate) reduces hositility and aggression in patients with acute schizophrenia Proceedings of the 36th Annual Meeting of the American College of Neuropsychopharmacology; 1997 Dec 8-12; Waikoloa, Hawaii, USA 1997"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0107|cit108","unstructured":"Cantillon M Goldstein JM Efficacy of quetiapine fumarate in affective symptoms of schizophrenia Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 - Jun 4; Toronto, Ontario, Canada 1998"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0108|cit109","unstructured":"Cantillon M Goldstein JM Quetiapine fumarate reduces aggression and hostility in patients with schizophrenia Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 - Jun 4; Toronto, Ontario, Canada 1998"},{"issue":"2","key":"10.1002\/14651858.CD009377.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0149-2918(03)80094-2","article-title":"A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia","volume":"25","author":"Chengappa","year":"2003","journal-title":"Clinical Therapeutics"},{"issue":"1-2","key":"10.1002\/14651858.CD009377.pub3-BIB0111|cit111","first-page":"154","article-title":"Seroquel: evidence for efficacy in the treatment of hostility and aggression","volume":"29","author":"Hellewell","year":"1998","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0112|cit112","unstructured":"Hellewell JSE Goldstein J Seroquel (quetiapine): efficacy in improving mood, aggression and hostility Proceedings of the 9th Congress of the Association of European Psychiatrists; 1998 Sep 20-24; Copenhagen, Denmark 1998"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0113|cit113","doi-asserted-by":"crossref","unstructured":"Hong W Arvanitis L Reduction of the positive symptoms of schizophrenia by '(ICI 204,636): results from phase II and III clinical trials Proceedings of the 9th European College of Neuropsychopharmacology Congress; 1996 Sep 21-25; Amsterdam, Netherlands 1996","DOI":"10.1016\/0924-977X(96)83185-3"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0116|cit114","volume-title":"Lorazepam versus a combination of haloperidol and promethazine in the acute management of agitation and aggression - a randomized controlled trial [thesis]","author":"Alexander","year":"2003"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD009377.pub3-BIB0114|cit115","first-page":"236","article-title":"TREC-India. A second arm of TREC","volume":"53","author":"Alexander","year":"2002","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0115|cit116","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1192\/bjp.185.1.63","article-title":"Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Pragmatic randomised trial of intramuscular lorazepam v haloperidol plus promethazine","volume":"185","author":"Alexander","year":"2004","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0117|cit117","unstructured":"NCT00455234 Rapid tranquilization of violent or agitated people in psychiatric emergency settings- a pragmatic randomized controlled trial of intramuscular olanzapine vs intramuscular haloperidol + promethazine http:\/\/www.clinicaltrials.gov 2007"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0119|cit118","unstructured":"Raveendran NS Rapid tranquillization of acutely agitated patients: intramuscular olanzapine vs haloperidol + promethazine - pragmatic randomized control trial Proceedings of the 5th European Congress on Violence in Clinical Psychiatry; 2007 Oct 25-27; Amsterdam, The Netherlands 2007"},{"issue":"7625","key":"10.1002\/14651858.CD009377.pub3-BIB0118|cit119","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/bmj.39341.608519.BE","article-title":"Rapid tranquillisation in psychiatric emergency setting in India: pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine","volume":"335","author":"Raveendran","year":"2007","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0120|cit120","unstructured":"Tharyan P A randomised controlled trial of intra-muscular lorazepam versus intra-muscular haloperidol+promethazine in the management of psychotic agitations and aggression http:\/\/www.controlled-trials.com 2002"},{"issue":"2","key":"10.1002\/14651858.CD009377.pub3-BIB0121|cit121","first-page":"418","article-title":"Similar rates of agitation, anxiety and insomnia in sedating and non-sedating antipsychotics: evaluating clinical trial results with aripiprazole, haloperidol and olanzapine","volume":"33","author":"Allen","year":"2007","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0122|cit122","doi-asserted-by":"crossref","unstructured":"Asadollahi S Heidari K Hatamabadi H Vafaee R Yunesian S Azadbakht A Efficacy and safety of valproic acid versus haloperidol in patients with acute agitation: results of a randomized, double-blind, parallel-group trial International Clinical Psychopharmacology 2015 142 50","DOI":"10.1097\/YIC.0000000000000064"},{"issue":"1-2","key":"10.1002\/14651858.CD009377.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0920-9964(97)88362-4","article-title":"The influence of pharmacotherapy on self-directed and externally-directed aggression in schizophrenia","volume":"29","author":"Beasley","year":"1998","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD009377.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/j.1875-9114.1998.tb03827.x","article-title":"A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation","volume":"18","author":"Bieniek","year":"1998","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD009377.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/(SICI)1099-1077(199801)13:1<17::AID-HUP937>3.0.CO;2-G","article-title":"A randomized controlled double blind study of zuclopenthixol acetate compared to haloperidol in acute psychosis","volume":"13","author":"Brook","year":"1998","journal-title":"Human Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD009377.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0002-7138(09)60909-2","article-title":"Drugs in aggressive behavior","volume":"21","author":"Campbell","year":"1982","journal-title":"Journal of the American Academy of Child Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD009377.pub3-BIB0127|cit127","first-page":"599","article-title":"The comparison study on curing agitation by haloperidol and chlorpromazine venoclysis","volume":"16","author":"Chen","year":"2004","journal-title":"Medical Journal of Chinese Civil Administration"},{"issue":"6","key":"10.1002\/14651858.CD009377.pub3-BIB0128|cit128","first-page":"363","article-title":"Intramuscular ziprasidone versus haloperidol in the treatment of acute agitation in schizophrenia","volume":"20","author":"Chen","year":"2008","journal-title":"Shanghai Archives of Psychiatry [\u4e0a\u6d77\u7cbe\u795e\u533b\u5b66] [\u4e0a\u6d77\u7cbe\u795e\u91ab\u5b78]"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD009377.pub3-BIB0129|cit129","first-page":"S114","article-title":"A double-blind randomized clinical trial of rapid tranquilization with IM clonazepam and IM haloperidol in agitated psychotic patients with manic symptoms","volume":"38","author":"Chouinard","year":"1993","journal-title":"Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0130|cit130","unstructured":"Chouinard G Safadi G Beauclair L The management of acutely schizophrenic patients newly admitted from the emergency room: A double-blind clinical trial comparing zuclopenthixol acetate and liquid haloperidol Proceedings of the 5th World Congress of Biological Psychiatry; 1991 Jun 9-14; Florence, Italy Amsterdam, Netherlands Excerpta Medica 1991 35 43"},{"issue":"11","key":"10.1002\/14651858.CD009377.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1176\/appi.ps.52.11.1510","article-title":"Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia","volume":"52","author":"Citrome","year":"2001","journal-title":"Psychiatric Services"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0132|cit132","unstructured":"Citrome LL Volavka J Czobor P Nolan K Lieberman JA Lindenmayer J-P Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA 2003"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0133|cit133","unstructured":"Citrome LL Volavka J Czobor P Sheitman BB Lindenmayer J-P McEvoy JP Atypical antipsychotics and hostility in schizophrenia: A double-blind study Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA 2001"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0134|cit134","unstructured":"Citrome LL Volavka J Czobor P Sheitman BB Lindenmayer J-P McEvoy JP Atypical antipsychotics and hostility in schizophrenia: A double-blind study Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA 2002"},{"issue":"4","key":"10.1002\/14651858.CD009377.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1176\/jnp.2006.18.4.509","article-title":"Aggression and quantitative MRI measures of caudate in patients with chronic schizophrenia or schizoaffective disorder","volume":"18","author":"Hoptman","year":"2006","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences"},{"issue":"2","key":"10.1002\/14651858.CD009377.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/01.jcp.0000117424.05703.29","article-title":"Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol","volume":"24","author":"Volavka","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0137|cit137","unstructured":"Colonna L Martin P Gerard D Long-term study of the effectiveness and tolerance of amisulpride versus haloperidol Proceedings of the 96th Congres de Psychiatrie et de Neurologie de Langue Francaise; 1998 May 10-15; Saint Paul, France 1998"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0138|cit138","unstructured":"Conde BL Sobreveg EE Sionzon MP A randomized trial of oral risperidone versus intramuscular haloperidol in the emergency treatment of acute psychotic agitation ASEAN Journal of Psychiatry 2011 29 36"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0139|cit139","unstructured":"Crandall D Pikalov A Kostic D Kaplita S Berman R McQuade R Is sedation needed for effective reduction of acute schizophrenia symptoms? Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta, Georgia, USA 2005"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009377.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"S296","DOI":"10.1016\/S0924-977X(00)80324-7","article-title":"Risperidone oral solution versus intramuscular haloperidol for control of psychotic agitation","volume":"10","author":"Currier","year":"2000","journal-title":"European Neuropsychopharmacology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009377.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"S289","DOI":"10.1016\/S0924-977X(00)80305-3","article-title":"An overview of the efficacy and safety of rapid acting intramuscular ziprasidone","volume":"10","author":"Daniel","year":"2000","journal-title":"European Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD009377.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"S299","DOI":"10.1016\/S0924-977X(03)92001-3","article-title":"Efficacy of intramuscular ziprasidone without adjunctive benzodiazepines","volume":"13","author":"Daniel","year":"2003","journal-title":"European Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD009377.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00004850-200401000-00002","article-title":"The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy","volume":"19","author":"Daniel","year":"2004","journal-title":"International Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD009377.pub3-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0920-9964(00)90816-8","article-title":"Intramuscular (IM) ziprasidone: a novel treatment for the short term management of agitated psychotic patients","volume":"41","author":"Lucey","year":"2000","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0145|cit145","unstructured":"Modell S Daniel D Stock E Wilber R Marcus R Carson W Intramuscular aripiprazole treatment for acute agitation in patients with psychosis Proceedings of the 24th Collegium Internationale Neuro-Psychopharmacologicum Congress; 2004 June 20-24; Paris, France 2004"},{"issue":"2","key":"10.1002\/14651858.CD009377.pub3-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0022-3956(01)00052-8","article-title":"Validation of the behavioural activity rating scale (BARS): a novel measure of activity in agitated patients","volume":"36","author":"Swift","year":"2002","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0147|cit147","unstructured":"Swift RH Harrigan EP Kammen DP A comparison of intramuscular (IM) ziprasidone with IM haloperidol Proceedings of the 9th Congress of the Association of European Psychiatrists; 1998 Sep 20-24; Copenhagen, Denmark 1998"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0148|cit148","doi-asserted-by":"crossref","unstructured":"Swift RH Harrigan EP Kammen DP A comparison of intramuscular ziprasidone with intramuscular haloperidol Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 - Jun 4; Toronto, Ontario, Canada 1998","DOI":"10.1016\/S0924-9338(99)80613-0"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0149|cit149","doi-asserted-by":"crossref","unstructured":"Swift RH Harrigan EP Van Kammen D Casey DE A comparison of fixed dose, intramuscular (IM) ziprasidone with flexible dose, IM haloperidol Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31 - Nov 4; Paris, France 1998","DOI":"10.1016\/S0924-9338(99)80613-0"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0150|cit150","doi-asserted-by":"crossref","unstructured":"Swift RH Harrigan EP Van-Kammen D A comparison of fixed-dose intramuscular (IM) ziprasidone with flexible-dose IM haloperidol Proceedings of the 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 1998 Jul 12-16; Glasgow, UK 1998","DOI":"10.1016\/S0924-977X(98)80348-9"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0151|cit151","unstructured":"Yocca F Daniel D Stock E Oren D Marcus R Carson W Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis Proceedings of the 43rd Annual Meeting of the American College of Neuro-Psychopharmacology; 2004 Dec 12-16; San Juan, Puerto Rico 2004"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0152|cit152","unstructured":"\u6a0a\u51cc\u59ff \u66f9\u7acb\u65b0 \u6c2f\u666e\u567b\u5428\u6ce8\u5c04\u6db2\u4e0e\u6c1f\u54cc\u5576\u9187\u6ce8\u5c04\u6db2\u6cbb\u7597\u7cbe\u795e\u5206\u88c2\u75c7\u5174\u594b\u6fc0\u8d8a\u5bf9\u7167\u7814\u7a76 \u4e2d\u5916\u5065\u5eb7\u6587\u6458 2012 31 2"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1176\/ajp.126.11.1670","article-title":"Comparison of haloperidol and fluphenazine in disturbed children","volume":"126","author":"Faretra","year":"1970","journal-title":"American Journal of Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD009377.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1592\/phco.29.8.930","article-title":"Intramuscular haloperidol versus intramuscular olanzapine for treatment of acute agitation: A cost-minimization study","volume":"29","author":"Freeman","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0155|cit155","first-page":"236","article-title":"Haloperidol in controlling the symptoms of acute psychoses. Part II: A double blind evaluation of haloperidol and trifluoperazine","volume":"8","author":"Goldstein","year":"1966","journal-title":"Current Therapeutic Research"},{"issue":"10","key":"10.1002\/14651858.CD009377.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1177\/0091270004267807","article-title":"Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia","volume":"44","author":"Harvey","year":"2004","journal-title":"Journal of Clinical Pharmacology"},{"issue":"5","key":"10.1002\/14651858.CD009377.pub3-BIB0157|cit157","first-page":"276","article-title":"A comparative study of the effect of modern electroconvulsive therapy on the agitated behavior of psychotic patients","volume":"14","author":"Huang","year":"2004","journal-title":"Journal of Clinical Psychological Medicine [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0158|cit158","unstructured":"\u848b\u5408\u840d \u7f57\u6bc5\u5e73 Olanzapine and haloperidol in the treatment of schizophrenia comparative study of excited agitation [Google Translate] Sichuan Mental Health [\u56db\u5ddd\u7cbe\u795e\u536b\u751f] 2009 43 4"},{"issue":"2","key":"10.1002\/14651858.CD009377.pub3-BIB0159|cit159","first-page":"22","article-title":"The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms","volume":"62","author":"Jones","year":"2001","journal-title":"Journal of Clinical Psychological Medicine [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"1","key":"10.1002\/14651858.CD009377.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0920-9964(00)90383-9","article-title":"Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo","volume":"41","author":"Kane","year":"2000","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0161|cit161","unstructured":"Eli Lilly Beasley 1996a - olz vs placebo vs hpl (N America) (as supplied 2004) Data on file 2001"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0162|cit162","unstructured":"Eli Lilly Beasley 1997 - olz vs hpl (international) (as supplied 2004) Data on file 2001"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0163|cit163","unstructured":"Eli Lilly Tollefson 1997 - olz vs hpl (as supplied 2004) Data on file 2001"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0164|cit164","unstructured":"Kinon BJ Basson MS Tollefson GD Gender-specific prolactin response to treatment with olanzapine versus haloperidol in schizophrenia Proceedings of the 9th Biennial Winter Workshop on Schizophrenia; 1998 Feb 7-13; Davos, Switzerland 1998"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD009377.pub3-BIB0165|cit165","first-page":"A60","article-title":"Effective resolution of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia with olanzapine","volume":"14","author":"Kinon","year":"2000","journal-title":"Journal of Psychopharmacology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD009377.pub3-BIB0166|cit166","first-page":"17","article-title":"Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia","volume":"62","author":"Kinon","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0167|cit167","unstructured":"Kinon BJ Wang L Stauffer VL A comparison of prolactin concentrations in the elderly during treatment with olanzapine, haloperidol, and risperidone Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23-26; San Francisco, California, USA 2001"},{"issue":"4","key":"10.1002\/14651858.CD009377.pub3-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1525-8610(04)70344-8","article-title":"The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients","volume":"4","author":"Kinon","year":"2003","journal-title":"Journal of the American Medical Directors Association"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0169|cit169","unstructured":"Kinon BJ Wang L Stauffer VL A comparison of prolactin concentrations in the elderly during treatment with olanzapine, haloperidol, and risperidone Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23-26; San Francisco, California, USA 2001"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0170|cit170","doi-asserted-by":"crossref","unstructured":"Krakowski M I Czobor P Depression and impulsivity as pathways to violence: implications for antiaggressive treatment Schizophrenia Bulletin 2014 886 94","DOI":"10.1093\/schbul\/sbt117"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0172|cit171","doi-asserted-by":"crossref","unstructured":"Krakowski M Czobor P Cholesterol and cognition in schizophrenia: A double-blind study of patients randomized to clozapine, olanzapine and haloperidol Schizophrenia Research 2011 27 33","DOI":"10.1016\/j.schres.2011.04.005"},{"issue":"1-3","key":"10.1002\/14651858.CD009377.pub3-BIB0171|cit172","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2009.02.006","article-title":"Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol","volume":"110","author":"Krakowski","year":"2009","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0177|cit173","unstructured":"Krakowski MI Clozapine and olanzapine in violent schizophrenics CRISP database (https:\/\/www-commons.cit.nih.gov\/crisp\/index.html)"},{"issue":"2","key":"10.1002\/14651858.CD009377.pub3-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/JCP.0b013e3181d47b5e","article-title":"A prospective longitudinal study of cholesterol and aggression in patients randomized to clozapine, olanzapine, and haloperidol","volume":"30","author":"Krakowski","year":"2010","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0175|cit175","doi-asserted-by":"crossref","unstructured":"Krakowski MI Czobor P Executive function predicts response to antiaggression treatment in schizophrenia: A randomized controlled trial Journal of Clinical Psychiatry 2012 74 80","DOI":"10.4088\/JCP.11m07238"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0176|cit176","doi-asserted-by":"crossref","unstructured":"Krakowski MI Czobor P Neurocognitive impairment limits the response to treatment of aggression with antipsychotic agents Schizophrenia Bulletin 2011 311 2","DOI":"10.1037\/e554362012-064"},{"issue":"6","key":"10.1002\/14651858.CD009377.pub3-BIB0173|cit177","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/archpsyc.63.6.622","article-title":"Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder","volume":"63","author":"Krakowski","year":"2006","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0178|cit178","unstructured":"NCT01123408 Clozapine and Olanzapine Treatment of Aggression http:\/\/ClinicalTrials.gov\/ct2\/show\/NCT01123408 2010"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0179|cit179","unstructured":"Krakowski M Czobor P A prospective longitudinal study of cholesterol and aggression in patients randomized to clozaplne, olanzapine and haloperidol Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15-18; Barcelona, Spain 2009"},{"issue":"5","key":"10.1002\/14651858.CD009377.pub3-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/JCP.0b013e3181855cd6","article-title":"Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients","volume":"28","author":"Krakowski","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD009377.pub3-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jpsychires.2004.04.010","article-title":"Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder","volume":"39","author":"Nolan","year":"2005","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0182|cit182","unstructured":"Lewis CF Haloperidol versus risperidone in the treatment of aggressive psychotic male inmates Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada 2006"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0183|cit183","unstructured":"NCT00203775 Efficacy of risperidone versus haloperidol in the treatment of aggression and hostility in psychotic inmates http:\/\/www.clinicaltrials.gov 2005"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0184|cit184","unstructured":"Li GL Tiapride intramuscular haloperidol in the treatment of acute schizophrenia excited state control study Nervous Diseases and Mental Health [\u795e\u7ecf\u75be\u75c5\u4e0e\u7cbe\u795e\u536b\u751f] 2005 456 7"},{"issue":"3","key":"10.1002\/14651858.CD009377.pub3-BIB0185|cit185","first-page":"150","article-title":"Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the in the treatment of schizophrenia with excitement and agitation","volume":"19","author":"Li","year":"2007","journal-title":"Shanghai Archives of Psychiatry [\u4e0a\u6d77\u7cbe\u795e\u533b\u5b66] [\u4e0a\u6d77\u7cbe\u795e\u91ab\u5b78]"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0186|cit186","unstructured":"\u6881\u829d\u56fd \u7f57\u7ef4\u8096 Clonazepam and haloperidol on patients with acute agitation control study Medical Journal of Chinese Civil Administration 2003 293 4"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0187|cit187","unstructured":"\u5218\u5e86\u6885 \u65e0\u62bd\u6410\u7535\u4f11\u514b\u6cbb\u7597\u7cbe\u795e\u5206\u88c2\u75c7\u4f34\u6fc0\u8d8a\u884c\u4e3a\u7597\u6548\u89c2\u5bdf\u53ca\u62a4\u7406\u5e72\u9884 \u4e34\u5e8a\u5fc3\u8eab\u75be\u75c5\u6742\u5fd7 2012 437 9"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0188|cit188","doi-asserted-by":"crossref","unstructured":"Mandel F Allen MH Lombardo I Early response to intramuscular ziprasidone as a predictor of end point response to oral ziprasidone Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA 2008","DOI":"10.1016\/S0920-9964(08)70806-5"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD009377.pub3-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"S420","DOI":"10.1016\/S0924-977X(06)70532-6","article-title":"Treatment of agitation caused by severe mental illness: data from the South London and Maudsley intensive care units trial evaluation (SLAMICUTE) study","volume":"16","author":"Mantua","year":"2006","journal-title":"European Neuropsychopharmacology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD009377.pub3-BIB0190|cit190","first-page":"18","article-title":"Efficacy of risperidone on positive features of schizophrenia","volume":"55","author":"McEvoy","year":"1994","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD009377.pub3-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/10401230490487025","article-title":"The utility of intramuscular ziprasidone in the management of acute psychotic agitation","volume":"16","author":"Mendelowitz","year":"2004","journal-title":"Annals of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0192|cit192","unstructured":"NCT00189995 Intramuscular clozapine in the management of aggression in schizophrenic patients http:\/\/www.clinicaltrials.gov 2005"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0193|cit193","unstructured":"NCT00631722 Multicenter, open-label, randomised, haloperidol-controlled study to evaluate seroquel as mono-therapy in the treatment of agitated symptoms in the patients with acute episode of schizophrenia http:\/\/www.clinicaltrials.gov 2008"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0194|cit194","unstructured":"NCT00797277 IM olanzapine versus IM haloperidol plus lorazepam for acute agitation in schizophrenia http:\/\/www.clinicaltrials.gov 2008"},{"issue":"2","key":"10.1002\/14651858.CD009377.pub3-BIB0195|cit195","first-page":"113","article-title":"Large dose of olanzapine in the ictus treatment of agitated symptoms of schizophrenia","volume":"11","author":"Pan","year":"2005","journal-title":"Journal of Clinical Psychosomatic Diseases [\u4e34\u5e8a\u5fc3\u8eab\u75be\u75c5\u6742\u5fd7]"},{"issue":"1-2","key":"10.1002\/14651858.CD009377.pub3-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/0920-9964(95)95498-X","article-title":"Relationship between creatine phosphokinase, psychotic symptoms and novel antipsychotic drugs","volume":"15","author":"Pathiraja","year":"1995","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD009377.pub3-BIB0197|cit197","first-page":"167","article-title":"Neuroleptics election and clinical outcomes in acute psychosis: A comparative study of risperidone versus other neuroleptics","volume":"20","author":"Pedros Rosello","year":"2004","journal-title":"Anales de Psiquiatria"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0198|cit198","unstructured":"\u88f4\u6811\u666f \u6768\u7ea2\u536b Oral risperidone treatment of schizophrenia clinical observation of excited agitation [Google Translate] Linchuang Jingshen Yixue Zazhi [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7] 2009 405 6"},{"issue":"6","key":"10.1002\/14651858.CD009377.pub3-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/00004714-200212000-00004","article-title":"Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia","volume":"22","author":"Muller","year":"2002","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD009377.pub3-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-0447.1998.tb10044.x","article-title":"Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol","volume":"98","author":"Puech","year":"1998","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2788.2009.01180.x","article-title":"The treatment of challenging behaviour in intellectual disabilities: cost-effectiveness analysis","volume":"53","author":"Romeo","year":"2009","journal-title":"Journal of Intellectual Disability Research"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0202|cit202","unstructured":"Tyrer P Neuroleptics in adults with aggressive challenging behaviour and intellectual disability http:\/\/www.controlled-trials.com 2003"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0203|cit203","unstructured":"Simpson G Mohammad AR Fauzia S Campaneau M Laska E Ninah R A comparison of rapid titration quetiapine and haloperidol in agitated adults in an emergency setting Proceedings of the 163rd Annual Meeting of the American Psychiatric Association; 2010 May 22-26; New Orleans, LA 2010"},{"issue":"2","key":"10.1002\/14651858.CD009377.pub3-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0165-1781(81)90046-9","article-title":"Aggression control and structuring of social relations among recently admitted schizophrenics","volume":"5","author":"Singh","year":"1981","journal-title":"Psychiatry Research"},{"issue":"3","key":"10.1002\/14651858.CD009377.pub3-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0033-3182(74)71262-2","article-title":"Haloperidol versus thioridazine for the treatment of psychogeriatric patients: A double-blind clinical trial","volume":"15","author":"Smith","year":"1974","journal-title":"Psychosomatics"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0206|cit206","unstructured":"Srinath G Shailaja B Sai PG Reddy KA A comparative study of injection haloperidol and promethazine vs. injection lorazepam in controlling acute psychotic agitation Indian Journal of Psychiatry 2010 S21"},{"issue":"4","key":"10.1002\/14651858.CD009377.pub3-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/00048677509159857","article-title":"Tranquilizers or anti-depressants for chronic schizophrenics: A long term study","volume":"9","author":"Teja","year":"1975","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD009377.pub3-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0196-0644(05)82660-5","article-title":"Droperidol versus haloperidol for chemical restraint of agitated and combative patients","volume":"21","author":"Thomas","year":"1992","journal-title":"Annals of Emergency Medicine"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0209|cit209","first-page":"220","article-title":"Physical restraints for agitated patients in psychiatric emergency hospitals in Rio de Janeiro, Brazil: a predictive model","volume":"31","author":"Coutinho","year":"2005","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0214|cit210","unstructured":"Huf G Rapid safe tranquillisation for acutely disturbed people attending public psychiatric emergency clinics in Rio de Janeiro http:\/\/www.controlled-trials.com 2002"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD009377.pub3-BIB0210|cit211","first-page":"187","article-title":"TREC I. Background","volume":"53","author":"Huf","year":"2002","journal-title":"Schizophrenia Research"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD009377.pub3-BIB0211|cit212","first-page":"187","article-title":"TREC III. The protocol and progress of TREC","volume":"53","author":"Huf","year":"2002","journal-title":"Schizophrenia Research"},{"issue":"11","key":"10.1002\/14651858.CD009377.pub3-BIB0212|cit213","first-page":"1","article-title":"TREC-Rio trial: A randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms","volume":"2","author":"Huf","year":"2002","journal-title":"BMC Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD009377.pub3-BIB0213|cit214","first-page":"236","article-title":"TREC II. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro, Brazil","volume":"53","author":"Huf","year":"2002","journal-title":"Schizophrenia Research"},{"issue":"7417","key":"10.1002\/14651858.CD009377.pub3-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1136\/bmj.327.7417.708","article-title":"Rapid tranquillisation for agitated patients in emergency psychiatric rooms: A randomised trial of midazolam versus haloperidol plus promethazine","volume":"327","author":"TREC","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0216|cit216","first-page":"279","article-title":"High-dose haloperidol therapy: Its effectiveness and a comparison with electroconvulsive treatment","volume":"4","author":"Ungvari","year":"1982","journal-title":"Journal of Psychiatric Treatment and Evaluation"},{"issue":"3","key":"10.1002\/14651858.CD009377.pub3-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1600-0447.1981.tb00673.x","article-title":"Haloperidol, thioridazine and placebo in mentally subnormal patients-serum levels and clinical effects","volume":"63","author":"Vaisanen","year":"1981","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009377.pub3-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.1016\/S0924-977X(02)80465-5","article-title":"Oral risperidone in the management of agitated behavior in emergency settings","volume":"12","author":"Veser","year":"2002","journal-title":"European Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD009377.pub3-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00131746-200603000-00005","article-title":"Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial","volume":"12","author":"Veser","year":"2006","journal-title":"Journal of Psychiatric Practice"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0220|cit220","doi-asserted-by":"crossref","unstructured":"Vives Vilagut R Duno R Planet N Garcia G Payes M Marinosa M Testing the intranasal route for administration of haloperidol in emergency room: Generation of efficacy data to support clinical practice Clinical Therapeutics 2015 e152","DOI":"10.1016\/j.clinthera.2015.05.435"},{"issue":"1","key":"10.1002\/14651858.CD009377.pub3-BIB0221|cit221","first-page":"23","article-title":"Curative effect of risperidone with BDZs in the treatment of excitement and agitate with schizophrenia in acute phase","volume":"13","author":"Wan","year":"2005","journal-title":"Heath Psychology Journal"},{"issue":"2","key":"10.1002\/14651858.CD009377.pub3-BIB0222|cit222","first-page":"88","article-title":"A multicenter study of risperidone treatment for acute agitation in patients with schizophrenia","volume":"37","author":"Wang","year":"2004","journal-title":"Chinese Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD009377.pub3-BIB0223|cit223","first-page":"271","article-title":"Safety and efficacy of quetiapine and haloperidol in the treatment of schizophrenia with excitement and agitation","volume":"17","author":"Wang","year":"2005","journal-title":"Shanghai Archives of Psychiatry [\u4e0a\u6d77\u7cbe\u795e\u533b\u5b66] [\u4e0a\u6d77\u7cbe\u795e\u91ab\u5b78]"},{"issue":"1","key":"10.1002\/14651858.CD009377.pub3-BIB0224|cit224","first-page":"126","article-title":"The use of midazolam in acutely agitated psychiatric patients","volume":"26","author":"Wyant","year":"1990","journal-title":"Psychopharmacology Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD009377.pub3-BIB0225|cit225","first-page":"31","article-title":"Zetidoline compared with haloperidol in a double blind clinical study","volume":"28","author":"Zapletalek","year":"1986","journal-title":"Activitas Nervosa Superior"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0226|cit226","unstructured":"Daniel DG Crandall D Manos G McQuade RD Gutierrez-Esteinou R Pikalov AA Transitioning from intramuscular (IM) to oral aripiprazole in patients with schizophrenia Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada 2006"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009377.pub3-BIB0227|cit227","first-page":"163","article-title":"The emergency treatment of acutely agitated psychotic schizophrenia patient","volume":"11","author":"Davis","year":"2008","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD009377.pub3-BIB0228|cit228","first-page":"475","article-title":"Rapid tranquilization: the efficacy of oral concentrate","volume":"46","author":"Dubin","year":"1985","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0229|cit229","doi-asserted-by":"crossref","unstructured":"Esmailian M Ahmadi O Taheri M Zamani M Comparison of haloperidol and midazolam in restless management of patients referred to the Emergency DepartmeNT: PDF: A double-blinded, randomized clinical trial Journal of Research in Medical Sciences 2015 844 9","DOI":"10.4103\/1735-1995.170598"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0230|cit230","unstructured":"Herrera M Double-blind study with risperidone vs haloperidol in schizophrenic patients with agitation and\/or aggression Proceedings of the 8th World Congress of Psychiatry; 2005 Sep 10-15; Cairo, Egypt 2005"},{"issue":"3","key":"10.1002\/14651858.CD009377.pub3-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/JCP.0b013e3181db8715","article-title":"Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan","volume":"30","author":"Hsu","year":"2010","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD009377.pub3-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"S469","DOI":"10.1016\/S0924-977X(10)70691-X","article-title":"Intramuscular aripiprazole versus injectable haloperidol in treatment of acute psychotic agitation","volume":"20","author":"Istikoglou","year":"2010","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0233|cit233","doi-asserted-by":"crossref","unstructured":"Kong BG Shim JC Lee SK Comparison of the effects of intramuscular antipsychotics injection in the treatment of acute agitation in psychosis European Neuropsychopharmacology 2009 S525 S6","DOI":"10.1016\/S0924-977X(09)70833-8"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD009377.pub3-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"S445","DOI":"10.1016\/S0924-977X(06)70577-6","article-title":"Risperidone oral solution, therapeutic possibility in treatment of acute and agitated psychotic patients","volume":"16","author":"Lasic","year":"2006","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0235|cit235","unstructured":"Li C Zhu S Wang H Chen H Yu Y Liu D Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the Shanghai Archives of Psychiatry [\u4e0a\u6d77\u7cbe\u795e\u533b\u5b66] [\u4e0a\u6d77\u7cbe\u795e\u91ab\u5b78] 2007 150 2"},{"issue":"4","key":"10.1002\/14651858.CD009377.pub3-BIB0236|cit236","first-page":"48","article-title":"Clinical evaluation on treatment of acute-agitation in schizophrenia with zipraside injection","volume":"15","author":"Lu","year":"2006","journal-title":"China Pharmaceuticals"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0237|cit237","unstructured":"NCT00859872 Efficacy and safety of risperidone oral solution combination clonazepam versus haloperidol intramuscular (IM) injection for treatment of acute psychotic agitation in schizophrenia http:\/\/www.clinicaltrials.gov 2009"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0238|cit238","unstructured":"NCT00866645 A study to evaluate the efficacy and safety of intramuscular levosulpiride in patients with agitation of schizophrenia http:\/\/www.clinicaltrials.gov 2009"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0239|cit239","doi-asserted-by":"crossref","unstructured":"Shim JC Kong BG Lee SG Kim YH The effect of intramuscular olanzapine in the treatment of acute agitation in patient with psychotic symptoms European Neuropsychopharmacology 2009 S512 S3","DOI":"10.1016\/S0924-977X(09)70811-9"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0240|cit240","unstructured":"Si T Zhong HJ Yun'Ai S Qin TM Qing LK De YP A multi-site,open-label, randomised, haloperidol-controlled study to evaluate quetiapine as monotherapy in the treatment of agitated acute schizophrenia Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA 2009"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0241|cit241","unstructured":"Slotnick VB Management of the acutely agitated psychiatric patient with parental neuroleptics: The comparitive symptom effectiveness profiles of haloperidol and chlorpromazine Proceedings of the 5th World Congress of Psychiatry; 1971 Nov 28 - Dec 4; Mexico City, Mexico 1971"},{"issue":"5","key":"10.1002\/14651858.CD009377.pub3-BIB0242|cit242","first-page":"752","article-title":"A clinical trial of injectable molindone (Moban(R))","volume":"32","author":"Smythies","year":"1982","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0243|cit243","doi-asserted-by":"crossref","unstructured":"Vasquez-Gomez F The use of midazolam for control of acutely agitated outpatients in psychiatry emergency Proceedings of the 7th World Congress of Biological Psychiatry; 2001 Jul 1-6; Berlin, Germany 2001","DOI":"10.3109\/15622970009150597"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0244|cit244","unstructured":"Wang R-C Li L-H Zhao Y-C Ziprasidone made in China and haloperidol in treating acute onset of schizophrenia: a randomized, single blinded, double modelling, parallel control study Chinese Journal of Clinical Rehabilitation 2005 83 5"},{"issue":"5","key":"10.1002\/14651858.CD009377.pub3-BIB0245|cit245","first-page":"364","article-title":"The second phase clinical trials of intramuscular ziprasidone for the treatment of acute psychotic agitation of the schizophrenia","volume":"7","author":"Wang","year":"2007","journal-title":"Nervous Diseases and Mental Health [\u795e\u7ecf\u75be\u75c5\u4e0e\u7cbe\u795e\u536b\u751f]"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0246|cit246","unstructured":"Yildiz A Turgay A Alpay M Sachs GS Risperidone versus haloperidol in adult psychiatric emergencies Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA 2003 Nr259"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0247|cit247","unstructured":"\u5f20\u5e86\u5a25 \u738b\u521a \u5f20\u73b2 \u738b\u96ea \u7f57\u70af \u8def\u4e9a\u6d32 Control study of acute agitation in schizophrenia risperidone oral solution merger clonazepam tablets treatment [Google Translate] \u4e2d\u534e\u533b\u5b66\u4f1a\u7b2c\u5341\u6b21\u5168\u56fd\u7cbe\u795e\u533b\u5b66\u5b66\u672f\u4f1a\u8bae 2012 89 91"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0248|cit248","unstructured":"\u53f6\u840c \u623f\u8302\u80dc \u674e\u4e50\u534e \u8d75\u9756\u5e73 Domestic ziprasidone mesylate injection in the treatment of acute agitation of schizophrenia Journal of the Xinxiang Medical College [\u65b0\u4e61\u533b\u5b66\u9662\u5b66\u62a5] 2009 63 5"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0249|cit249","unstructured":"\u5468\u5fb7\u7965 \u848b\u5e78\u884d \u5f90\u6e05 \u65b9\u99a8\u6021 \u590f\u9e23\u534e \u9646\u96c5\u5a1c \u5229\u57f9\u916e\u53e3\u670d\u6db2\u5408\u5e76\u6c2f\u785d\u897f\u6cee\u6cbb\u7597\u7cbe\u795e\u5206\u88c2\u75c7\u5174\u594b\u6fc0\u8d8a\u75c7\u72b6\u7684\u968f\u673a\u5bf9\u7167\u7814\u7a76 \u4e2d\u56fd\u5065\u5eb7\u5fc3\u7406\u5b66\u6742\u5fd7 2012 1123 4"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0250|cit250","unstructured":"NCT00838032 Pilot study to evaluate the efficacy and safety of quetiapine fumarate instant-release (seroquel ir) in controlling agitation and aggressive symptoms in the acute treatment of patients with schizophrenia http:\/\/www.clinicaltrials.gov 2009"},{"issue":"11","key":"10.1002\/14651858.CD009377.pub3-BIB0251|cit251","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003082.pub3","article-title":"Haloperidol versus placebo for schizophrenia","author":"Adams","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD009377.pub3-BIB0252|cit252","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007445.pub2","article-title":"Chlorpromazine for psychosis induced aggression or agitation","author":"Ahmed","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD009377.pub3-BIB0253|cit253","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009412","article-title":"Risperidone for psychosis induced aggression or agitation","author":"Ahmed","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7066","key":"10.1002\/14651858.CD009377.pub3-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0255|cit255","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890423363.45859","volume-title":"Practice Guideline for the Treatment of Patients With Schizophrenia","author":"American Psychiatric Association","year":"2006"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD009377.pub3-BIB0257|cit257","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003729.pub2","article-title":"Olanzapine IM or velotab for acutely disturbed\/agitated people with suspected serious mental illnesses","author":"Belgamwar","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD009377.pub3-BIB0258|cit258","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002304.pub2","article-title":"Clotiapine for acute psychotic illnesses","author":"Berk","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0260|cit260","volume-title":"British National Formulary","author":"British National Formulary","year":"2011"},{"issue":"4","key":"10.1002\/14651858.CD009377.pub3-BIB0261|cit261","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"issue":"1","key":"10.1002\/14651858.CD009377.pub3-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1017\/S1742646410000142","article-title":"Audit of the rapid tranquilization policy in the 2gether NHS foundation trust","volume":"7","author":"Choudhury","year":"2011","journal-title":"Journal of Psychiatric Intensive Care"},{"issue":"2","key":"10.1002\/14651858.CD009377.pub3-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/01688638908400888","article-title":"Development of a scale for assessment of agitation following traumatic brain injury","volume":"11","author":"Corrigan","year":"1989","journal-title":"Journal of Clinical and Experimental Neuropsychology"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0264|cit264","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"issue":"6","key":"10.1002\/14651858.CD009377.pub3-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"12","key":"10.1002\/14651858.CD009377.pub3-BIB0267|cit267","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003441.pub3","article-title":"'As required' medication regimens for seriously mentally ill people in hospital","author":"Douglas-Hall","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD009377.pub3-BIB0268|cit268","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009922.pub2","article-title":"De-escalation techniques for psychosis-induced aggression or agitation","author":"Du","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8746","key":"10.1002\/14651858.CD009377.pub3-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/0140-6736(91)90201-Y","article-title":"Publication bias in clinical research","volume":"337","author":"Easterbrook","year":"1991","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD009377.pub3-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"7","key":"10.1002\/14651858.CD009377.pub3-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD009377.pub3-BIB0273|cit273","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003079.pub3","article-title":"Benzodiazepines for psychosis-induced aggression or agitation","author":"Gillies","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD009377.pub3-BIB0274|cit274","first-page":"42","article-title":"Does loxapine have \"atypical\" properties? Clinical evidence","volume":"60","author":"Glazer","year":"1999","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0276|cit276","first-page":"217","article-title":"Clinical Global Impression","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0278|cit278","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"11","key":"10.1002\/14651858.CD009377.pub3-BIB0279|cit279","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005146.pub3","article-title":"Haloperidol plus promethazine for psychosis-induced aggression","author":"Huf","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD009377.pub3-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.annemergmed.2010.05.037","article-title":"Randomized controlled trial of intramuscular droperidol versus midazolam for violence and acute behavioral disturbance: the DORM study","volume":"56","author":"Isbister","year":"2010","journal-title":"Annals of Emergency Medicine"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0281|cit281","unstructured":"Janssen-Cilag Ltd Haldol (haloperidol) 5mg\/ml Injection. Summary of product characteristics http:\/\/www.medicines.org.uk\/emc\/medicine\/7267\/spc\/haldol+injection\/"},{"issue":"4","key":"10.1002\/14651858.CD009377.pub3-BIB0282|cit282","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000525.pub3","article-title":"Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses","author":"Jayakody","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0283|cit283","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0284|cit284","first-page":"799","article-title":"The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia","volume":"10","author":"Kay","year":"1962","journal-title":"Psychological Reports"},{"issue":"12","key":"10.1002\/14651858.CD009377.pub3-BIB0285|cit285","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002830.pub3","article-title":"Droperidol for psychosis-induced aggression or agitation","author":"Khokhar","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD009377.pub3-BIB0286|cit286","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009830.pub2","article-title":"Haloperidol for long-term aggression in psychosis","author":"Khushu","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD009377.pub3-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD009377.pub3-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/schbul\/sbl025","article-title":"Is the superior efficacy of new generation antipsychotics an artifact of LOCF?","volume":"33","author":"Leucht","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"7400","key":"10.1002\/14651858.CD009377.pub3-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","article-title":"Pharmaceutical industry sponsorship and research outcome and quality: Systematic review","volume":"326","author":"Lexchin","year":"2003","journal-title":"BMJ"},{"issue":"12","key":"10.1002\/14651858.CD009377.pub3-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"130-41","DOI":"10.1016\/j.brainresbull.2009.01.005","article-title":"The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice","volume":"79","author":"L\u00f3pez-Munoz","year":"2009","journal-title":"Brain Research Bulletin"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"9263","key":"10.1002\/14651858.CD009377.pub3-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(00)04337-3","article-title":"The CONSORT statement:revised recommendations for improving the quality of reports of parallel-group randomised trials","volume":"357","author":"Moher","year":"2001","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD009377.pub3-BIB0295|cit295","first-page":"327","article-title":"Treatment of acute agitation in psychotic disorders","volume":"26","author":"Mohr","year":"2005","journal-title":"Neuro Endocrinology Letters"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1477-7525-9-18","article-title":"Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room","volume":"9","author":"Montoya","year":"2011","journal-title":"Health Quality Life Outcomes"},{"issue":"3","key":"10.1002\/14651858.CD009377.pub3-BIB0297|cit297","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002084.pub2","article-title":"Containment strategies for people with serious mental illness","author":"Muralidharan","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0298|cit298","unstructured":"National Health Service The prescribing preview report on antipsychotic drugs, available to general practitioners in August 2009, is reproduced here for readers with an interest in patterns and trends of prescribing Impact: Prescribing and Dispensing Newsletter. http:\/\/www.nhsbsa.nhs.uk\/PrescriptionServices\/Documents\/PrescriptionServices\/Impact_Dec_09_8p.pdf 4 6"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0299|cit299","volume-title":"The short term-management of disturbed\/violent behaviour in inpatient psychiatric settings and emergency departments","volume":"25","author":"National Institute for Clinical Excellence","year":"2005"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0300|cit300","unstructured":"National Institute for Clinical Excellence Violence and aggression: short-term management in mental health, health and community settings nice.org.uk\/guidance\/ng10 2015"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/978-3-540-74806-9_16","article-title":"Midazolam and other benzodiazepines","volume":"182","author":"Olkkola","year":"2008","journal-title":"Handbook of Experimental Pharmacology"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"2","key":"10.1002\/14651858.CD009377.pub3-BIB0303|cit303","first-page":"1","article-title":"What is new in rapid tranquillisation?","volume":"7","author":"Parker","year":"2010","journal-title":"Journal of Psychiatric Intensive Care"},{"issue":"2","key":"10.1002\/14651858.CD009377.pub3-BIB0304|cit304","first-page":"71-83","article-title":"Management of behavioural emergencies","volume":"2","author":"Pereira","year":"2007","journal-title":"Journal of Psychiatric Intensive Care"},{"issue":"1-2","key":"10.1002\/14651858.CD009377.pub3-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1017\/S1742646408001234","article-title":"Establishing gold standard approaches to rapid tranquillisation: A review and discussion of the evidence of the safety and efficacy of medications used","volume":"4","author":"Pratt","year":"2008","journal-title":"Journal of Psychiatric Intensive Care"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0306|cit306","first-page":"301","article-title":"Droperidol dropped; consultants not consulted: A survey of the practice of rapid tranquillisation by consultant psychiatrists in the west of Scotland","volume":"27","author":"Reid","year":"2003","journal-title":"Psychiatric Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD009377.pub3-BIB0307|cit307","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001163","article-title":"Seclusion and restraint for people with serious mental illnesses","author":"Sailas","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1192\/apt.bp.109.007310","article-title":"Management of acute agitation in psychosis: an evidence-based approach in the USA","volume":"17","author":"Schleifer","year":"2011","journal-title":"Advances in Psychiatric Treatment"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/9780470712184.ch12","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Sch\u00fcnemann","year":"2008"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0310|cit310","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatri Scandinavica. Supplementum"},{"issue":"5","key":"10.1002\/14651858.CD009377.pub3-BIB0311|cit311","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jclinepi.2008.12.011","article-title":"A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers","volume":"62","author":"Thorpe","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7417","key":"10.1002\/14651858.CD009377.pub3-BIB0312|cit312","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1136\/bmj.327.7417.708","article-title":"Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine","volume":"327","author":"TREC Collaborative Group","year":"2003","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD009377.pub3-BIB0313|cit313","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organistation-based intervention in health and health care: A systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0314|cit314","doi-asserted-by":"crossref","unstructured":"Vangala R Ahmed U Ahmed R Loxapine inhaler for psychosis-induced aggression Cochrane Database of Systematic Reviews 2012","DOI":"10.1002\/14651858.CD010190"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0315|cit315","unstructured":"World Health Organization WHO Essential Medicines List http:\/\/whqlibdoc.who.int\/hq\/2011\/a95053_eng.pdf"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0316|cit316","unstructured":"World Health Organization WHO Model List of Essential Medicines http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/EML_2015_FINAL_amended_NOV2015.pdf?ua=1 2015"},{"issue":"4","key":"10.1002\/14651858.CD009377.pub3-BIB0317|cit317","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009801","article-title":"Quetiapine for psychosis-induced aggression or agitation","author":"Wilkie","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD009377.pub3-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1192\/bjp.179.6.503","article-title":"Extrastriatal and striatal D2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia","volume":"179","author":"Xiberas","year":"2001","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009377.pub3-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1176\/ajp.143.1.35","article-title":"The Overt Aggression Scale for the objective rating of verbal and physical aggression","volume":"143","author":"Yudofsky","year":"1986","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD009377.pub3-BIB0321|cit321","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1176\/jnp.9.4.541","article-title":"The Overt Agitation Severity Scale for the objective rating of agitation","volume":"9","author":"Yudofsky","year":"1997","journal-title":"Journal of Neuropsychiatry"},{"issue":"10","key":"10.1002\/14651858.CD009377.pub3-BIB0322|cit322","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009377","article-title":"Haloperidol (rapid tranquilisation) for psychosis induced aggression or agitation","author":"Powney","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD009377.pub3-BIB0323|cit323","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009377.pub2","article-title":"Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation)","author":"Powney","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD009377.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T21:46:32Z","timestamp":1719351992000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009377.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,7,31]]},"references-count":323,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009377.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,31]]}}}